Hepatitis D market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3% in the above mentioned forecast period.
Hepatitis D is a viral infection which is caused by the hepatitis D virus and causes inflammation of the liver. This further result in the impairment of liver functions and causes long term liver problems such as liver cancer and scarring. Hepatitis D virus (HDV) is found only in the people who are infected with hepatitis B virus. Symptoms of hepatitis D include abdominal pain, jaundice, joint pain, dark-coloured urine, loss of appetite, fatigue, nausea and vomiting.
Rise in the prevalence of hepatitis D and hepatitis B, growing healthcare expenditure, alcohol abuse, high consumption of unbalanced diet, rising incidence of intravenous drug abuse, growing government funding and rising initiatives by government and private organisations to spread awareness about the disease are the factors that will expand the hepatitis D market.
Rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the hepatitis D market in the forecast period of 2021-2028.
However, high cost of treatment, lack of awareness about the preventive measures and complications associated with hepatitis D such as liver failure, liver cirrhosis and hepatocellular carcinoma are the factors that will hinder the market growth and will further challenge the hepatitis D market in the forecast period mentioned above.
View Detailed Report@ https://www.databridgemarketresearch.com/reports/global-hepatitis-d-market
The major players covered in the hepatitis D market report are BIOSIDUS, F. Hoffmann-La Roche Ltd., Zydus Cadila, NanoGen Healthcare Pvt. Ltd., AMEGA Biotech, Rhein-Minapharm, PROBIOMED SA de CV, 3SBio Group, Eiger BioPharmaceuticals, Arrowhead Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., Antios Therapeutics, Inc., PharmaEssentia Corporation, Replicor, Janssen Pharmaceuticals, Inc., Gilead Sciences, Inc., Hetero, Aurobindo Pharma, Mylan N.V., Apotex Inc., ViiV Healthcare group of companies, GlaxoSmithKline plc, Cipla Inc., Sun Pharmaceutical Industries Ltd., and Merck Sharp Dohme Corp., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Global Hepatitis D Market Scope and Market Size
The hepatitis D market is segmented on the basis of type, treatment, diagnosis, transmission, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the hepatitis D market is segmented into acute hepatitis D and chronic hepatitis D.
- On the basis of treatment, the hepatitis D market is segmented into interferon alpha, lamivudine, liver transplant and others. Others have been sub-segmented into emerging drugs which are further divided into peginterferon lambda, bulevirtide, lonafarnib and JNJ-73763989.
- On the basis of diagnosis, the hepatitis D market is segmented into blood tests, elastography, liver biopsy, serologic testing and others.
- On the basis of transmission, the hepatitis D market is segmented into exposure to infected blood, contaminated needles, blood and plasma product transfusion and others.
- On the basis of end-users, the hepatitis D market is segmented into clinic, hospital and others.
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]
